COMBINATION THERAPY IS NOT ASSOCIATED WITH IMPROVED RATES OF CLINICAL OR ENDOSCOPIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH USTEKINUMAB OR VEDOLIZUMAB

Angus W. Jeffrey  1     Sherman Picardo     Shankar Menon     Kenji So     Kannan Venugopal    
1 Royal Perth Hospital, Perth, Australia

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing